Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic)

Abstract Background Lupus animal model has shown that arsenic trioxide (ATO), a treatment of acute promyelocytic leukaemia, could be effective in SLE. This is the first clinical study to determine the safety and efficacy of a short course of intravenous ATO in patients with active SLE. Methods This...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Mohamed Hamidou, Antoine Néel, Joel Poupon, Zahir Amoura, Mikael Ebbo, Jean Sibilia, Jean-Francois Viallard, Benjamin Gaborit, Christelle Volteau, Jean Benoit Hardouin, Eric Hachulla, François Rieger
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2021-03-01
coleção:	Arthritis Research & Therapy
Assuntos:	Systemic lupus erythematosus Autoimmune diseases Treatment Arsenic trioxide Phase II clinical trial
Acesso em linha:	https://doi.org/10.1186/s13075-021-02454-6
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!